Actively Recruiting
Bougie Diameter on Outcomes in Laparoscopic Sleeve Gastrectomy
Led by General Committee of Teaching Hospitals and Institutes, Egypt · Updated on 2026-02-18
100
Participants Needed
1
Research Sites
41 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Laparoscopic sleeve gastrectomy (LSG) has become an increasingly popular bariatric procedure since its first performance by Hess and Hess in 1988 as a component of the biliopancreatic diversion-duodenal switch (BPD-DS) procedure, which was modified from Scopinaro's biliopancreatic diversion (BPD) and DeMeester's technique. In the early part of the twenty-first century, it was popularized as a first-step intervention before BPD or gastric bypass in the super obese and high-risk group of patients by Regan et al. Due to the unexpected good results in terms of weight loss and resolution of comorbidities, coupled with the simplicity of performing the procedure requiring intervention on only the stomach, sleeve gastrectomy gained status as a stand-alone bariatric procedure as demonstrated by Baltasar et al. The basic principle of LSG is to create a narrow stomach along the lesser curvature, depending on the left gastric artery, using a calibration bougie as a template to perform a vertical partial gastrectomy, resecting the greater curvature and fundus of the stomach according to the International Sleeve Gastrectomy Expert Panel Consensus Statement by Rosenthal et al. The procedure has demonstrated excellent outcomes in terms of weight loss and comorbidity resolution, making it one of the most commonly performed bariatric procedures worldwide according to the IFSO Worldwide Survey by Angrisani et al. Bougie Size Considerations and Rationale The selection of an appropriate bougie size during laparoscopic sleeve gastrectomy represents a critical technical decision that significantly influences both immediate surgical outcomes and long-term patient results. Calibration bougies serve as internal templates to standardize the gastric sleeve diameter and ensure consistent sleeve geometry across different surgeons and institutions, as described by Parikh et al. The diameter of the bougie directly determines the final gastric volume and the degree of restriction achieved, which in turn affects weight loss efficacy, food tolerance, and complication rates. Bougie sizes in current clinical practice typically range from 32-French (Fr) to 50-Fr, with most centers utilizing sizes between 34-Fr and 42-Fr according to the survey by Gagner et al. Small bougie sizes (32-36-Fr) create a more restrictive sleeve with potentially enhanced weight loss but may be associated with increased risks of stenosis, food intolerance, and gastroesophageal reflux disease as reported by Sakran et al. Medium bougie sizes (38-42-Fr) represent a compromise between restriction and safety, offering adequate weight loss while maintaining acceptable complication rates as demonstrated by Weiner et al. Large bougie sizes (44-50-Fr) provide greater sleeve capacity with improved food tolerance and potentially reduced leak rates, though concerns exist regarding long-term weight loss maintenance according to Abdallah et al. The rationale for comparing different bougie sizes stems from the ongoing debate regarding the optimal balance between surgical efficacy and safety. Recent meta-analyses have suggested that larger bougie sizes may be associated with reduced gastric leak rates without significantly compromising weight loss outcomes. However, the majority of existing evidence comes from retrospective observational studies with inherent limitations including selection bias, confounding variables, and lack of standardized outcome measures as noted by Shi et al. The current study aims to provide definitive prospective evidence comparing small (36-Fr) versus X large (larger than 40-Fr) bougie sizes in a randomized controlled trial design. Furthermore, the impact of bougie size on comorbidity resolution remains inadequately studied. Bariatric surgery has demonstrated remarkable efficacy in resolving obesity-related comorbidities, with diabetes remission rates ranging from 53% to 63% as reported by Schauer et al. and hypertension resolution rates varying from 8% to 50% depending on the specific criteria used according to Sjöström et al. The relationship between sleeve geometry, as determined by bougie size, and comorbidity resolution mechanisms requires further investigation to optimize patient outcomes and surgical technique selection.
CONDITIONS
Official Title
Bougie Diameter on Outcomes in Laparoscopic Sleeve Gastrectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 70 years undergoing laparoscopic sleeve gastrectomy as a primary bariatric procedure
- Body mass index (BMI) �35 kg/m2 regardless of comorbidities, or BMI 30-34.9 kg/m2 with metabolic disease and poor response to nonsurgical treatments
- Metabolic diseases include type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, asthma, fatty liver, kidney disease, polycystic ovarian syndrome, infertility, pseudotumor cerebri, bone and joint diseases
- Bariatric surgery decision approved by a multidisciplinary team
- Ability to provide written informed consent
- Ability to complete questionnaires and attend follow-up visits
- Stable weight within 5% for 3 months before surgery
- Normal or mild upper gastrointestinal findings on preoperative endoscopy
- Negative or minimal gastroesophageal reflux symptoms (GERD-Q score �8 or less)
You will not qualify if you...
- Previous gastric surgeries or bariatric procedures
- American Society of Anesthesiologists (ASA) score greater than 4
- Pregnant or planning pregnancy during the study period
- Significant esophageal or gastric conditions including moderate to severe reflux esophagitis, hiatal or paraesophageal hernia, Barrett's esophagus, active peptic ulcers, or large gastric polyps
- Severe gastroesophageal reflux disease defined by GERD-Q score greater than 8, daily proton pump inhibitor use with breakthrough symptoms, or endoscopic evidence of moderate to severe esophagitis
- Coagulation disorders or anticoagulation therapy that cannot be safely stopped
- Known allergy or hypersensitivity to silicon or bougie materials
- Active substance abuse or psychiatric conditions that may interfere with study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The surgical department of Medical Research Institute Hospital, Alexandria University
Alexandria, Alexandria Governorate, Egypt, 21531
Actively Recruiting
Research Team
M
Mohamed Ashour, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here